These data indicate that Shp2 regulates CA916798 and cisplatin resistance in SCLC through the AKT pathway and that interfering with the AKT pathway alters CA916798 expression and cisplatin resistance. This evidence concerns the gene AKT1 and small cell lung carcinoma.